Decreased insulin requirements after LAR-octreotide but not after lanreotide in an acromegalic patient

Pituitary

Volumn 4, Issue 4, 2001, Pages 275-278

  Webb, Susan ^a   Ortega, Emilio ^a   Rodríguez Espinosa, José ^a   Mato, María Eugènia ^a   Corcoy, Rosa ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Acromegaly; Diabetes mellitus; Glucagon; Hypoglycemia; Somatostatin analogues

Indexed keywords

ANGIOPEPTIN; C PEPTIDE; GLUCAGON; GLUCOSE; GROWTH HORMONE; HYDROCORTISONE; IMMUNOREACTIVE INSULIN; INSULIN; ISOPHANE INSULIN; LEVOTHYROXINE; LONG ACTING DRUG; OCTREOTIDE; OMEPRAZOLE; ORAL ANTIDIABETIC AGENT; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; TESTOSTERONE; TESTOSTERONE ENANTATE;

ACROMEGALY; ADULT; CARBOHYDRATE ABSORPTION; CASE REPORT; DIABETES MELLITUS; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG RECEPTOR BINDING; GASTRINOMA; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GROWTH HORMONE BLOOD LEVEL; HUMAN; HYPOPITUITARISM; INSULIN BLOOD LEVEL; INSULIN HYPOGLYCEMIA; MALE; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RADIOSURGERY; SHORT SURVEY; TESTOSTERONE BLOOD LEVEL;

EID: 0035470162     PISSN: 1386341X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1020710800842     Document Type: Short Survey

References (14)

1. Shimon I, Melmed S. Structure and function of somatostatin receptors in growth hormone control. J Endocrinol 1997;155(Suppl 1):S3-S6.
2. Patel YC, Srikant CB. Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hsstr 1-5). Endocrinology 1994;135:2814-2817.
3. Reisine T, Bell GI. Molecular biology of somatostatin receptors. Endocrine Rev 1995;16:427-442.
4. Hofland LJ, Lamberts SWJ. Somatostatin receptors and disease: Role of receptors subtypes. Baillière's Clin Endocrinol Metab 1996;10:163-176.
5. Plewe G, Noelken G, Krause U, Beyer J, del Pozo E. Suppression of growth hormone and somatomedin C by long-acting somatostatin analog SMS 201-995 in type I diabetes mellitus. Hormone Res 1987;27:7-12.
6. Gerich J. Role of somatostatin and its analogues in the pathogenesis and treatment of diabetes mellitus. Metabolism 1990;39 (Suppl 2):52-54.
7. Lamberts SWJ. Non-pituitary actions of somatostatin. A review on the therapeutic role of SMS 201-995 (sandostatin). Acta Endocrinol 1986 Suppl 276:41-55.
8. Giustina A, Barkan A, Casanueva F, Cavagnini F, Frohman L, Ho K, et al. Criteria for cure of acromegaly. A consensus statement. J Clin Endocrinol Metab 2000;85:526-529.
9. Tomassetti P, Migliori M, Gullo L. Slow-release lanreotide treatment in endocrine gastrointestinal tumors. Am J Gastroenterol 1998;93:1468-1471.
10. Lehnert H, Beyer J, Weber P, Krause U, Schrezenmeier J. Treatment of severe reactive hypoglycemia with a somatostin analogue (SMS 201-995). Arch Int Med 1990;150:2401-2402.
11. Wägner AM, Webb SM, Corcoy R. Benzodiacepine interruption. Does it cause hypoglycemia? Diab Care 1999;22:2099.
12. Kannan V. Diazepam test of growth hormone secretion. Horm Metab Res 1981;13:390-393.
13. Kubota A, Yamada Y, Kagimoto S, Shimatsu A, Imamura M, Tsuda K, et al. Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of endocrine tumors. J Clin Invest 1994;93:1321-1325.
14. Gama R, Marks V, Wright J, Teale JD. Octreotide exacerbated fasting hypoglycemia in a patient with a proinsulinoma; the glucostatic importance of pancreatic glucagon. Clin Endocrinol 1995;43:117-120.